206 related articles for article (PubMed ID: 25457019)
21. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Monk P; Liu G; Stadler WM; Geyer S; Huang Y; Wright J; Villalona-Calero M; Wade J; Szmulewitz R; Gupta S; Mortazavi A; Dreicer R; Pili R; Dawson N; George S; Garcia JA
Invest New Drugs; 2018 Oct; 36(5):919-926. PubMed ID: 30083962
[TBL] [Abstract][Full Text] [Related]
22. Cabozantinib use in renal cell carcinoma.
Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
[TBL] [Abstract][Full Text] [Related]
23. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
24. Cabozantinib improves clinical outcomes in renal cancer.
Das M
Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
[No Abstract] [Full Text] [Related]
25. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
[TBL] [Abstract][Full Text] [Related]
26. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
27. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
28. Papillary renal cell carcinoma: current progress and future directions.
Twardowski PW; Mack PC; Lara PN
Clin Genitourin Cancer; 2014 Apr; 12(2):74-9. PubMed ID: 24629521
[TBL] [Abstract][Full Text] [Related]
29. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
Scagliotti GV; Di Maio M
Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
[No Abstract] [Full Text] [Related]
30. NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.
Elsada A; Adler AI
Lancet Oncol; 2017 Sep; 18(9):1153-1154. PubMed ID: 28800862
[No Abstract] [Full Text] [Related]
31. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
[TBL] [Abstract][Full Text] [Related]
32. Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.
Wang D; Lu Y; Nannapaneni S; Griffith CC; Steuer C; Qian G; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; He X; Chen ZG; Saba NF
Oral Oncol; 2021 Jan; 112():105074. PubMed ID: 33142224
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
34. MET Mutation Associated with Responsiveness to Crizotinib.
Waqar SN; Morgensztern D; Sehn J
J Thorac Oncol; 2015 May; 10(5):e29-e31. PubMed ID: 25898962
[No Abstract] [Full Text] [Related]
35. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
36. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
Shea M; Huberman MS; Costa DB
J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
[No Abstract] [Full Text] [Related]
37. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
Harshman LC; Choueiri TK
Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
[TBL] [Abstract][Full Text] [Related]
38. Lord of the rings: a promising novel treatment for renal cell carcinoma?
Johansson M
Eur Urol; 2011 May; 59(5):745-6. PubMed ID: 21276657
[No Abstract] [Full Text] [Related]
39. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
[No Abstract] [Full Text] [Related]
40. Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas.
Yan B; Lim M; Zhou L; Kuick CH; Leong MY; Yong KJ; Aung L; Salto-Tellez M; Chang KT
J Clin Pathol; 2013 Nov; 66(11):985-91. PubMed ID: 23801497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
